NeuroOne Q1 FY26 net loss narrows to $2.09 million; product revenue rises to $2.39 million

NeuroOne Medical

NeuroOne Medical

NMTC

0.00
  • NeuroOne Medical Technologies reported a net loss of USD 2.09 million for three months ended March 31, 2026, narrowing from USD 2.27 million a year earlier.
  • Revenue rose 72.46% to USD 2.39 million, while gross profit margin slipped 1.8 percentage points to 53.8%.
  • Operating loss narrowed to USD 2.1 million from USD 2.68 million.
  • Cash and cash equivalents totaled USD 2.8 million as of March 31, 2026, with management citing substantial doubt about ability to continue as a going concern and saying cash may not fund operating expenses for at least 12 months from filing date.
  • Completed limited market release of OneRF TN Ablation System in March 2026, evaluating distribution options; also closed a March 2026 private placement raising USD 670,400 in gross proceeds.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-054749), on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.